Antiangiogenic therapies for non-small-cell lung cancer

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Vasculotropin 100%
• Antiangiogenic Therapy 100%
• Biological Marker 50%
• Malignant Neoplasm 50%
• Metastasis 50%
• Tumor Growth 50%
• Protein Tyrosine Kinase 50%
• Carboplatin 50%
• Overall Survival 50%
• Chemotherapy 50%
• Paclitaxel 50%
• Lung Cancer 50%
• Bevacizumab 50%
• Monotherapy 50%
• Monoclonal Antibody 50%
• Angiogenesis Inhibitor 50%
• Protein Tyrosine Kinase Inhibitor 50%
• Vasculotropin Receptor 50%

Medicine and Dentistry

• Angiogenesis 100%
• Non Small Cell Lung Cancer 100%
• Antiangiogenic Therapy 100%
• Mediator 66%
• Vasculotropin 66%
• Biological Marker 33%
• Monoclonal Antibody 33%
• Tumor Progression 33%
• Metastatic Carcinoma 33%
• Overall Survival 33%
• Lung Cancer 33%
• Carboplatin 33%
• Paclitaxel 33%
• Protein Tyrosine Kinase 33%
• Cancer Therapy 33%
• Bevacizumab 33%
• Monotherapy 33%
• Angiogenesis Inhibitor 33%
• Tyrosine-Kinase Inhibitor 33%
• Vasculotropin Receptor 33%

Keyphrases

• Non-small Cell Lung Cancer (NSCLC) 100%
• Angiogenesis 100%
• Antiangiogenic Therapy 100%
• Monoclonal Antibody 33%
• Tumor Metastasis 33%
• Tumor Growth 33%
• Overall Survival 33%
• Monotherapy 33%
• Chemotherapy 33%
• Improved Survival 33%
• Non-squamous Non-small Cell Lung Cancer 33%
• Carboplatin 33%
• Paclitaxel 33%
• Cancer Therapy 33%
• Bevacizumab 33%
• Antiangiogenic Agents 33%
• Predictive Biomarker 33%